Form4insider filings, from the source

SEC Form 4 · accession 0001140361-15-023567

Alaunos Therapeutics, Inc. · TCRT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners
Randal J Kirk
Director · 10% Owner
INTREXON CORP
10% Owner
Period of report
Jun 4, 2015
Accepted (ET)
Jun 8, 2015 · 9:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001107421

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1,F2Jun 4, 2015J17,830,305—D0Iby Intrexon Corporation
Common StockF1,F3Jun 4, 2015J3,479,006—A3,479,006Iby R.J. Kirk DOT
Common StockF1,F3Jun 4, 2015J23,349—A23,349Iby JPK 2008
Common StockF1,F3Jun 4, 2015J23,504—A23,504Iby MGK 2008
Common StockF1,F3Jun 4, 2015J40,954—A40,954Iby ZSK 2008
Common StockF1,F3Jun 4, 2015J240—A240Iby Lotus
Common StockF1,F3Jun 4, 2015J53,245—A53,245Iby Staff 2001
Common StockF1,F3Jun 4, 2015J9,537—A9,537Iby Sr. Staff
Common StockF1,F3Jun 4, 2015J337,333—A337,333Iby JPK 2009
Common StockF1,F3Jun 4, 2015J358,386—A358,386Iby MGK 2009
Common StockF1,F3Jun 4, 2015J34,318—A34,318Iby ZSK 2009
Common StockF1,F3Jun 4, 2015J29,066—A29,066Iby ADC 2010
Common StockF1,F3Jun 4, 2015J154,181—A154,181Iby MGK 2011
Common StockF1,F3Jun 4, 2015J138,975—A138,975Iby JPK 2012
Common StockF1,F3Jun 4, 2015J61,262—A61,262Iby Kellie L. Banks LTT
Common StockF1,F4Jun 4, 2015J1,013,146—A2,359,608Iby Kapital Joe
Common StockF1,F4Jun 4, 2015J889,513—A889,513Iby Mascara Kaboom
Common StockF1,F4Jun 4, 2015J395,791—A395,791Iby Senior Staff 2008
Common StockF1,F4Jun 4, 2015J222,680—A222,680Iby Staff 2010
Common StockF1,F4Jun 4, 2015J111,339—A111,339Iby Incentive 2010
Common StockF1,F4Jun 4, 2015J352,477—A352,477Iby Senior Staff 2007
Common StockF1,F4Jun 4, 2015J176,238—A176,238Iby Staff 2007
Common StockF1,F4Jun 4, 2015J58,746—A58,746Iby Incentive 2007
Common StockF1,F4Jun 4, 2015J173,111—A173,111Iby Staff 2009
Common StockF1,F4Jun 4, 2015J86,556—A86,556Iby Incentive 2009
Common Stockholding———95,648D

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses